Efficacy of a short sandwich protocol, methotrexate, gemcitabine, L-asparaginase and dexamethasone chemotherapy combined with radiotherapy, in localised newly diagnosed NK/T-cell lymphoma: A French retrospective study.
NK-T cell lymphoma
asparaginase activity
non-Hodgkin lymphoma
radio-chemotherapy
Journal
British journal of haematology
ISSN: 1365-2141
Titre abrégé: Br J Haematol
Pays: England
ID NLM: 0372544
Informations de publication
Date de publication:
05 2023
05 2023
Historique:
revised:
24
01
2023
received:
24
11
2022
accepted:
27
01
2023
medline:
4
5
2023
pubmed:
18
2
2023
entrez:
17
2
2023
Statut:
ppublish
Résumé
Extranodal NK/T-cell lymphoma, nasal type is a rare and aggressive form of lymphoma, historically associated with poor prognosis. We report here the results of a retrospective multi-centre study evaluating the efficacy of MGAD (methotrexate, gemcitabine, L-asparaginase and dexamethasone) regimen (two cycles) combined with 'sandwich' radiotherapy in 35 patients with localised newly diagnosed extranodal NK/T-cell lymphoma. Thirty-two patients (91%) reached complete remission. With a long median follow-up of 59.6 months, progression-free and overall survival at 2 and 5 years were 71%, 80% and 53%, 73%, respectively. Around one third of the patients experienced relapse within a median time of 14.5 months. Side-effects were manageable with grades 3-4 cytopenias, mucositis and infection in 50%, 24% and 21% of the cases, respectively. Monitoring of asparaginase activity was performed in 13 patients and showed inactivation of the drug in seven (54%) patients. Our results indicate that a short therapy by sandwich MGAD chemoradiotherapy is a tolerable and effective treatment option in localised newly diagnosed extranodal NK/T-cell lymphoma patients.
Substances chimiques
Gemcitabine
0
Asparaginase
EC 3.5.1.1
Methotrexate
YL5FZ2Y5U1
Dexamethasone
7S5I7G3JQL
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
673-681Informations de copyright
© 2023 The Authors. British Journal of Haematology published by British Society for Haematology and John Wiley & Sons Ltd.
Références
Wang H, Fu B-B, Gale RP, Liang Y. NK−/T-cell lymphomas. Leukemia. 2021;35(9):2460-8.
Tse E, Zhao W-L, Xiong J, Kwong Y-L. How we treat NK/T-cell lymphomas. J Hematol Oncol. 2022;15(1):74.
Reneau JC, Shindiapina P, Braunstein Z, Youssef Y, Ruiz M, Farid S, et al. Extranodal natural killer/T-cell lymphomas: current approaches and future directions. J Clin Med. 2022;11(10):2699.
Ribrag V, Ell Hajj M, Janot F, Girinsky T, Domenge C, Schwaab G, et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia. 2001;15(7):1123-6.
Li Y-X, Yao B, Jin J, Wang WH, Liu YP, Song YW, et al. Radiotherapy as primary treatment for stage IE and IIE nasal natural killer/T-cell lymphoma. J Clin Oncol off J Am Soc Clin Oncol. 2006;24(1):181-9.
Wang B, Li X-Q, Ma X, Hong X, Lu H, Guo Y. Immunohistochemical expression and clinical significance of P-glycoprotein in previously untreated extranodal NK/T-cell lymphoma, nasal type. Am J Hematol. 2008;83(10):795-9.
Yong W, Zheng W, Zhu J, Zhang Y, Wang X, Xie Y, et al. L-asparaginase in the treatment of refractory and relapsed extranodal NK/T-cell lymphoma, nasal type. Ann Hematol. 2009;88(7):647-52.
Jaccard A, Gachard N, Marin B, Rogez S, Audrain M, Suarez F, et al. Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. Blood. 2011;117(6):1834-9.
Ji J, Liu T, Xiang B, Liu W, He C, Chen X, et al. A study of gemcitabine, l-asparaginase, ifosfamide, dexamethasone and etoposide chemotherapy for newly diagnosed stage IV, relapsed or refractory extranodal natural killer/T-cell lymphoma, nasal type. Leuk Lymphoma. 2014;55(12):2955-7.
Wang J-H, Wang L, Liu C-C, Xia ZJ, Huang HQ, Lin TY, et al. Efficacy of combined gemcitabine, oxaliplatin and pegaspargase (P-gemox regimen) in patients with newly diagnosed advanced-stage or relapsed/refractory extranodal NK/T-cell lymphoma. Oncotarget. 2016;7(20):29092-101.
Yamaguchi M, Tobinai K, Oguchi M, Ishizuka N, Kobayashi Y, Isobe Y, et al. Phase I/II study of concurrent chemoradiotherapy for localized nasal natural killer/T-cell lymphoma: Japan clinical oncology group study JCOG0211. J Clin Oncol off J Am Soc Clin Oncol. 2009;27(33):5594-600.
Bi X, Xia Y, Zhang W, Sun P, Liu PP, Wang Y, et al. Radiotherapy and PGEMOX/GELOX regimen improved prognosis in elderly patients with early-stage extranodal NK/T-cell lymphoma. Ann Hematol. 2015;94(9):1525-33.
Zang J, Li C, Luo S-Q, Wang JH, Xu M, Zhao LN, et al. Early radiotherapy has an essential role for improving survival in patients with stage I-II nasal-type of NK/T cell lymphoma treated with L-asparaginase-containing chemotherapy-a single institution experience. Ann Hematol. 2015;94(4):583-91.
Tsai H-J, Lin S-F, Chen C-C, Chen TY, Su WC, Hwang WL, et al. Long-term results of a phase II trial with frontline concurrent chemoradiotherapy followed by consolidation chemotherapy for localized nasal natural killer/T-cell lymphoma. Eur J Haematol. 2015;94(2):130-7.
Michot J-M, Mazeron R, Danu A, Lazarovici J, Ghez D, Antosikova A, et al. Concurrent etoposide, steroid, high-dose Ara-C and platinum chemotherapy with radiation therapy in localised extranodal natural killer (NK)/T-cell lymphoma, nasal type. Eur J Cancer. 2015;51(16):2386-95.
Li J, Li Y, Zhong M, Liu W, Liu X, Li J, et al. A multicenter retrospective comparison of sequential versus Sandwich Chemoradiotherapy for stage IE-IIE Extranodal natural killer/T-cell lymphoma, nasal type. J Cancer. 2018;9(9):1598-606.
Kwong YL, Kim SJ, Tse E, Oh SY, Kwak JY, Eom HS, et al. Sequential chemotherapy/radiotherapy was comparable with concurrent chemoradiotherapy for stage I/II NK/T-cell lymphoma. Ann Oncol off J Eur Soc Med Oncol. 2018;29(1):256-63.
Wang H-Y, Niu S-Q, Yang Y-Y, Li YY, Chen HB, Zhang YJ. Promising clinical outcomes of sequential and “Sandwich” chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage IE /IIE extranodal natural killer/T-cell lymphoma. Cancer Med. 2018;7(12):5863-9.
Ahn HK, Kim SJ, Hwang DW, Ko YH, Tang T, Lim ST, et al. Gemcitabine alone and/or containing chemotherapy is efficient in refractory or relapsed NK/T-cell lymphoma. Invest New Drugs. 2013;31(2):469-72.
Zhou Z, Li X, Chen C, Li X, Zhang L, Li L, et al. Effectiveness of gemcitabine, pegaspargase, cisplatin, and dexamethasone (DDGP) combination chemotherapy in the treatment of relapsed/refractory extranodal NK/T cell lymphoma: a retrospective study of 17 patients. Ann Hematol. 2014;93(11):1889-94.
Wei W, Wu P, Li L, Zhang Z-H. Effectiveness of pegaspargase, gemcitabine, and oxaliplatin (P-GEMOX) chemotherapy combined with radiotherapy in newly diagnosed, stage IE to IIE, nasal-type, extranodal natural killer/T-cell lymphoma. Hematol Amst Neth. 2017;22(6):320-9.
Liu T, Zhu F, Xiao Y, Li Q, Liu X, Yang K, et al. Pegaspargase, gemcitabine, dexamethasone, and cisplatin (P-GDP) combined chemotherapy is effective for newly diagnosed extranodal NK/T-cell lymphoma: a retrospective study. Cancer Manag Res. 2018;10:5061-9.
Laurent C, Baron M, Amara N, Haioun C, Dandoit M, Maynadié M, et al. Impact of expert pathologic review of lymphoma diagnosis: study of patients from the French Lymphopath network. J Clin Oncol off J Am Soc Clin Oncol. 2017;35(18):2008-17.
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375-90.
International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med. 1993;329(14):987-94.
Kim SJ, Yoon DH, Jaccard A, Chng WJ, Lim ST, Hong H, et al. A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis. Lancet Oncol. 2016;17(3):389-400.
Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol off J Am Soc Clin Oncol. 2014;32(27):3059-68.
Yoon DH, Kim SJ, Jeong SH, Shin DY, Bae SH, Hong J, et al. Phase II trial of concurrent chemoradiotherapy with L-asparaginase and MIDLE chemotherapy for newly diagnosed stage I/II extranodal NK/T-cell lymphoma, nasal type (CISL-1008). Oncotarget. 2016;7(51):85584-91.
Jiang M, Zhang H, Jiang Y, Yang Q, Xie L, Liu W, et al. Phase 2 trial of “sandwich” L-asparaginase, vincristine, and prednisone chemotherapy with radiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer. 2012;118(13):3294-301.
Xu P-P, Xiong J, Cheng S, Zhao X, Wang CF, Cai G, et al. A phase II study of methotrexate, etoposide, dexamethasone and Pegaspargase sandwiched with radiotherapy in the treatment of newly diagnosed, stage IE to IIE Extranodal natural-killer/T-cell lymphoma, nasal-type. EBioMedicine. 2017;25:41-9.
Jiang M, Zhang L, Xie L, Zhang H, Jiang Y, Liu WP, et al. A phase II prospective study of the “Sandwich” protocol, L-asparaginase, cisplatin, dexamethasone and etoposide chemotherapy combined with concurrent radiation and cisplatin, in newly diagnosed, I/II stage, nasal type, extranodal natural killer/T-cell lymphoma. Oncotarget. 2017;8(30):50155-63.
Zhang L, Jiang M, Xie L, Zhang H, Jiang Y, Yang QP, et al. Five-year analysis from phase 2 trial of “sandwich” chemoradiotherapy in newly diagnosed, stage IE to IIE, nasal type, extranodal natural killer/T-cell lymphoma. Cancer Med. 2016;5(1):33-40.
Kim SJ, Yang D-H, Kim JS, Kwak JY, Eom HS, Hong DS, et al. Concurrent chemoradiotherapy followed by L-asparaginase-containing chemotherapy, VIDL, for localized nasal extranodal NK/T cell lymphoma: CISL08-01 phase II study. Ann Hematol. 2014;93(11):1895-901.
Wang L, Wang Z-H, Chen X-Q, Wang K-F, Huang H-Q, Xia Z-J. First-line combination of GELOX followed by radiation therapy for patients with stage IE/IIE ENKTL: an updated analysis with long-term follow-up. Oncol Lett. 2015;10(2):1036-40.
Lee J, Suh C, Park YH, Ko YH, Bang SM, Lee JH, et al. Extranodal natural killer T-cell lymphoma, nasal-type: a prognostic model from a retrospective multicenter study. J Clin Oncol off J Am Soc Clin Oncol. 2006;24(4):612-8.
Wang L, Wang H, Wang J, Xia ZJ, Lu Y, Huang HQ, et al. Post-treatment plasma EBV-DNA positivity predicts early relapse and poor prognosis for patients with extranodal NK/T cell lymphoma in the era of asparaginase. Oncotarget. 2015;6(30):30317-26.
Liu Z-L, Bi X-W, Liu P-P, Lei D-X, Jiang W-Q, Xia Y. The clinical utility of circulating Epstein-Barr virus DNA concentrations in NK/T-cell lymphoma: a meta-analysis. Dis Markers. 2018;2018:1961058.
Wang X-X, Li P-F, Bai B, Gao Y, Rong QX, Cai QQ, et al. Differential clinical significance of pre-, interim-, and post-treatment plasma Epstein-Barr virus DNA load in NK/T-cell lymphoma treated with P-GEMOX protocol. Leuk Lymphoma. 2019;60(8):1917-25.
Silverman LB, Supko JG, Stevenson KE, Woodward C, Vrooman LM, Neuberg DS, et al. Intravenous PEG-asparaginase during remission induction in children and adolescents with newly diagnosed acute lymphoblastic leukemia. Blood. 2010;115(7):1351-3.
Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, Marini B. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2018;59(8):1797-806.
Huynh VT, Love A, English M, Lin CH. Drug monitoring of Asparaginase activity to detect silent inactivation in pediatric acute lymphoblastic leukemia patients receiving peg-Asparaginase. Blood. 2018;132(Supplement 1):3968.
Jaccard A, Chaubard S, Benoist J-F, Couronne L, Philippe L, Gyan E, et al. Monitoring Asparaginase activity in 21 patients with Extranodal NK/T-cell lymphoma shows a very high proportion of Asparaginase inactivation. Blood. 2018;132(Supplement 1):5351.
Kim HJ, Ock C-Y, Kim TM, Lee SH, Lee JY, Jung S, et al. Comparison of native Escherichia coli L-Asparaginase versus Pegylated Asparaginase, in combination with Ifosfamide, methotrexate, etoposide, and prednisolone, in Extranodal NK/T-cell lymphoma, nasal type. Cancer Res Treat. 2018;50(3):670-80.
Sakata K, Fuwa N, Kodaira T, Aratani K, Ikeda H, Takagi M, et al. Analyses of dose-response in radiotherapy for patients with mature T/NK-cell lymphomas according to the WHO classification. Radiother Oncol J Eur Soc Ther Radiol Oncol. 2006;79(2):179-84.
Sun P, Wang Y, Yang H, Chen C, Nie M, Sun XQ, et al. Combination of anti-PD-1 antibody, Anlotinib and Pegaspargase “Sandwich” with radiotherapy in localized natural killer/T cell lymphoma. Front Immunol. 2022;13:766200.